{"analyses":[{"ciLowerLimit":"0.56","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.12","estimateComment":"Hazard ratio was calculated from the stratified Cox regression model with placebo as the comparator, with two-sided 95% CI. Stratification factor was the number of prior line of therapies at randomization.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.093","pValueComment":"P-value was calculated from the one-sided stratified log-rank test. Stratification factor was the number of prior line of therapies at randomization.","paramType":"Hazard Ratio (HR)","paramValue":"0.79","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"7.8","upperLimit":"12.4","value":"10.3"},{"groupId":"OG001","lowerLimit":"4.8","upperLimit":"11.1","value":"7.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"126"},{"groupId":"OG001","value":"61"}],"units":"Participants"}],"description":"Overall survival was defined as the time in months from date of randomization to the date of death due to any cause. Participants without documentation of death at the time of the final collection were censored at the date the participant was last known to be alive, or the final collection date, whichever is earlier.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study for up to approximately 45 months.","id":"OG000","title":"AG-120"},{"description":"Participants received AG-120 matched placebo, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up or the sponsor ended the study for up to approximately 7 months. Participants who experienced disease progression and received placebo were allowed to cross over and receive AG-120.","id":"OG001","title":"Placebo"}],"paramType":"MEDIAN","populationDescription":"ITT population included all participants who were randomized, with the treatment group designated according to the randomization.","reportingStatus":"POSTED","timeFrame":"From date of randomization until the date of death due to any cause (Up to approximately 2 years)","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}